Early trial for cystic fibrosis drug halted
NCT ID NCT04375514
Summary
This early-stage study aimed to test the safety and effects of an experimental drug called ARO-ENaC. It involved healthy volunteers and people with cystic fibrosis to see how their bodies handled the drug and if it helped lung function. The study was terminated early, and its main goal was to gather initial safety information, not to prove the drug works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Nedlands, Washington, 6009, Australia
-
Research Site 2
Hamilton, 3204, Australia
-
Research Site 3
Chermside, Queensland, 4032, Australia
-
Research Site 4
South Brisbane, Queensland, 4101, Australia
-
Research Site 6
Grafton, Auckland, 1010, New Zealand
-
Research Site 7
Dunedin, 9054, New Zealand
-
Research Site 8
Christchurch, 8140, New Zealand
Conditions
Explore the condition pages connected to this study.